Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17182626 | 0.83 | ADRA2B (0.45) | ADRA2BGAAMAPTTSHRMAPK1 | |
| SCHEMBL30573342 | 0.82 | PRKCI (0.42) | ADRA2BGAAMAPTTSHRMAPK1 | |
| SCHEMBL1467075 | 0.82 | PRKCI (0.42) | ADRA2BGAAMAPTTSHRMAPK1 | |
| SCHEMBL26037690 | 0.81 | ADRA2B (0.50) | ADRA2BGAAMAPTTSHRMAPK1 | |
| SCHEMBL31175766 | 0.81 | ADRA2B (0.50) | ADRA2BGAAMAPTTSHRMAPK1 | |
| SCHEMBL26640991 | 0.79 | ADRA2B (0.42) | ADRA2BGAAMAPTTSHRMAPK1 | |
| SCHEMBL7239671 | 0.79 | TAAR1 (0.54) | ADRA2BMAPTMAPK1KDM4ETAAR1 | |
| SCHEMBL21089028 | 0.79 | ADRA2B (0.49) | ADRA2BGAAMAPTTSHRMAPK1 | |
| SCHEMBL4332045 | 0.79 | ADRA2B (0.49) | ADRA2BGAAMAPTTSHRMAPK1 | |
| SCHEMBL17726213 | 0.78 | ADRA2B (0.45) | ADRA2BGAAMAPTTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113396137-A | Method for producing 1,1, 1-trifluoro-2, 2-bisarylethane, and 1,1, 1-trifluoro-2, 2-bisarylethane | 中央硝子株式会社 | 2021-09-14 | — | — | CN | claimed |
| WO-2024105553-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS | NOVARTIS AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-20240158357-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4252856-A2 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | Oligomerix, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3611165-B1 | PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT | MITSUI CHEMICALS CROP & LIFE SOLUTIONS INC (JP) | 2023-08-16 | — | — | EP | disclosed |
| EP-3558950-B1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-11472776-B2 | Quinazolinones that inhibit the formation of tau oligomers and their method of use | OLIGOMERIX, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| CN-113396137-A | Method for producing 1,1, 1-trifluoro-2, 2-bisarylethane, and 1,1, 1-trifluoro-2, 2-bisarylethane | 中央硝子株式会社 | 2021-09-14 | — | — | CN | disclosed |
| WO-2021046286-A1 | HEPATITIS B ANTIVIRAL AGENTS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2021-03-11 | — | — | WO | disclosed |
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| US-7671095-B2 | Films and particles | THE TRUSTEES OF THE BOSTON UNIVERSITY (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671095-B2 | Films and particles | THE TRUSTEES OF THE BOSTON UNIVERSITY (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2009032124-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032124-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032116-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032116-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032123-A2 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032123-A2 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20080075718-A1 | Films and Particles | THE TRUSTEES OF THE BOSTON UNIVERSITY | 2008-03-27 | — | — | US | disclosed |
| US-20080075718-A1 | Films and Particles | THE TRUSTEES OF THE BOSTON UNIVERSITY | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | RORC, RORA, RORB | ADRA2B 1395/4885GAA 2473/4885MAPT 3807/4885 |
| US-20080075718-A1 | Films and Particles | APOB, PGF, ACTB | ADRA2B 2026/4885GAA 836/4885MAPT 246/4885 |
| US-11472776-B2 | Quinazolinones that inhibit the formation of tau oligomers and their method of use | MAPT, PSEN1, APP | ADRA2B 3014/4885GAA 370/4885MAPT 1/4885 |
| US-20240158357-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | MAPT, PSEN1, APP | ADRA2B 2718/4885GAA 359/4885MAPT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.